

Myeloma, MGUS & related conditions

A Guide for GPs



Disclaimer

This guide is provided for the benefit of healthcare professionals and is intended for a UK audience. It contains information obtained from reliable, highly regarded sources and the content has been peer reviewed.

Whilst we try to ensure the information provided is accurate, we do not accept liability arising from its use. As a medical professional you retain full responsibility for the care and treatment of your patients, and you should use your own clinical judgement and expertise appropriate to the circumstances of each patient.

Contents

1.	Introduction	4
2.	What is myeloma, smouldering myeloma and MGUS?	5
3.	The importance of early diagnosis	9
4.	Red flags of myeloma	10
5.	Requesting tests	12
6.	Interpreting test results	13
7.	Looking for trends and safety netting	15
8.	When to refer	16
9.	Managing MGUS in primary care	18
10.	Other conditions associated with monoclonal proteins	20
11.	Managing patients with myeloma in primary care	24
12.	References	26
13.	Further information	28

1. Introduction

This guide is written for General Practitioners (GPs) to help in the diagnosis of myeloma and monoclonal gammopathies. It focuses on the tests that can be requested in primary care, how to interpret these test results, and guidance on referral.

About myeloma

- Myeloma is a blood cancer that arises in the plasma cells of the bone marrow
- On average 5,900 people are diagnosed with myeloma every year in the UK
- 73% of myeloma diagnoses are in people aged over 65, but it affects younger people too
- Myeloma is 2–3 times more common in black people compared with white and Asian people
- Complications of myeloma include bone damage, anaemia, infections, and renal impairment
- Diagnosis after GP referral has a better survival than after diagnosis via emergency routes

2. What is myeloma, smouldering myeloma and MGUS?

Myeloma is a blood cancer that arises in the plasma cells of the bone marrow. Genetic alterations can lead to uncontrolled proliferation of these plasma cells and the secretion of high levels of abnormal and non-functional immunoglobulins (paraproteins). These changes can lead to complications including bone damage, anaemia, infections, and renal impairment.

Myeloma is classified according to the type of defective immunoglobulin (Ig) that is produced by the plasma cell clone. A single Y-shaped immunoglobulin consists of two identical heavy chains (type G, A, D, E or M) and two identical light chains (kappa or lambda). Light chains in the urine are commonly known as Bence Jones proteins (BJP). The majority of patients have IgG type myeloma. IgA is the next most common, with IgM, IgD and IgE types all rare.





Around 20% of patients have light chain myeloma, where the myeloma cells produce only light chains and no whole immunoglobulins. As only one type of light chain is produced, an abnormal serum free light chain (sFLC) kappa:lambda ratio indicates this type of myeloma, as well as high absolute levels of either kappa or lambda light chains. Light chain myeloma is particularly damaging to the kidneys as the light chains can accumulate and block the renal tubules.

Around 1–2% of myeloma cases are non-secretory, meaning that no measurable paraprotein is detected at all.

The current UK working definition of active myeloma comes from the International Myeloma Working Group (IMWG),¹ which lists myeloma-defining events (MDEs) as part of the diagnostic criteria, as noted in Table 1. These criteria include **CRAB** features (hyper**C**alcaemia, **R**enal, **A**naemia, **B**one), and three additional MDEs, known as **SLiM** criteria. This combination assists haematologists to diagnose myeloma sooner and start treatment earlier.

Table 1. Diagnostic criteria for active myeloma

Clonal bone marrow plasma cells $\geq 10\%$ or biopsy-proven bony or extramedullary plasmacytoma and one or more of the following **myeloma-defining events**:

- 
HyperC**alcaemia:** >2.75 mmol/L serum calcium or >0.25 mmol/L higher than the upper limit of normal
 - 
Renal insufficiency: serum creatinine >177 $\mu\text{mol/L}$ or creatinine clearance <40 ml/min
 - 
Anaemia: haemoglobin <100 g/L or >20 g/L below lower limit of normal
 - 
Bone lesions: ≥ 1 osteolytic lesion on X-ray, CT or PET/CT (>5 mm in size)
- **S**ixty percent or greater ($\geq 60\%$) clonal plasma cells in bone marrow
 - Ratio of abnormal **L**ight chains/normal light chains ≥ 100 , provided the involved light chain is >100 mg/L
 - >1 focal lesion on **M**RI (>5 mm in size)

Patients with active myeloma will, at some stage, have passed through two earlier phases of disease, monoclonal gammopathy of undetermined significance (MGUS) and smouldering myeloma as defined in Table 2.

Table 2. Definition of MGUS and smouldering myeloma

MGUS

- Pre-malignant
- <30 g/L serum paraprotein
- <10% clonal plasma cells
- No myeloma-defining events

Smouldering myeloma

- Malignant
- Early form of myeloma (usually progresses over time)
- ≥30 g/L serum paraprotein
- 10–60% clonal plasma cells
- No myeloma-defining events

In both MGUS and smouldering myeloma, a monoclonal protein (paraprotein) is present and there is evidence of proliferation of clonal plasma cells in the bone marrow, but patients usually show no symptoms. MGUS and smouldering myeloma are often picked up as an incidental finding, with a paraprotein being detected on routine blood tests.

Patients with active myeloma need to start treatment straight away to halt the disease process and stop further end organ damage. Those with smouldering myeloma are monitored regularly for signs of progression to active myeloma. The risk of progression from smouldering to active myeloma is summarised in Table 3.²

Table 3. Risk of progression from smouldering to active myeloma

Period after diagnosis	Approximate risk of progression to active myeloma during this period
0–5 years	50%
5–10 years	15%
10–20 years	10%

3.

The importance of early diagnosis

Primary care clinicians play a critical role in the early diagnosis of myeloma by being able to:

- Accurately test and refer patients presenting with symptoms of suspected myeloma
- Manage patients with low-risk MGUS, knowing when to seek advice or make a referral to haematology

Evidence shows that myeloma patients experience some of the longest delays to diagnosis of all cancer patients, and this remains the case despite national referral guidelines for suspected cancer.^{3,4} This is in part due to the vague and non-specific nature of symptoms.

A myeloma patient's route to diagnosis has an impact on survival. Diagnosis after presentation via GP referral has a better one-year survival than via an emergency presentation (88% vs 62%, respectively).⁵ Furthermore, 25% of myeloma patients who present as an emergency die within the first six months of diagnosis compared to <10% of those presenting via other routes.⁶

Patients presenting as emergencies often do so with acute and/or late-stage complications such as fractures, severe infections, acute renal failure, and spinal cord compression, with associated effects on function and quality of life. A study of cancer patients that presented as an emergency, found that, of 18 different cancer types, myeloma patients were the most likely to have had three or more prior GP consultations.⁷

Raising awareness of the typical signs and symptoms of myeloma may help GPs, and other healthcare professionals who first encounter potential myeloma patients, to suspect and investigate this cancer earlier and reduce the likelihood of emergency presentation.

4. Red flags of myeloma

Myeloma is often characterised by vague, non-specific symptoms that may be attributed to comorbidities or considered too non-specific to suggest cancer. It is critical to consider myeloma, however, when such symptoms arise, particularly in combination.

There are several red flag symptoms that should lead to a suspicion of myeloma:



Persistent or unexplained pain (>4–6 weeks, presenting as generalised or localised), particularly in the back or ribs



Pathological or fragility fractures, e.g. of the vertebra



Hypercalcaemia; reduction in renal function



Recurrent or persistent infections



Unexplained anaemia



Nosebleeds or unexplained bleeding



Unexplained breathlessness



Generally unwell – fatigue, weight loss, suspicion of underlying cancer



Unexplained peripheral neuropathy

It is critical to consider myeloma when such symptoms arise, particularly in combination. The following have a positive predictive value (PPV) >10 for myeloma.⁸

- **Hypercalcaemia**, plus any of the following:
 - two episodes of back pain
 - fracture; joint pain
 - rib pain
- **Leukopenia**, plus either of the following:
 - nosebleeds
 - fractures

As with many other cancers, a GP's underlying suspicion of cancer can be an important and powerful indicator to take further investigative tests.



5. Requesting tests

Some GPs have the option to request a 'myeloma screen' while others need to request the combination of individual tests, listed below:

- Full blood count
- Adjusted/corrected serum calcium
- Serum creatinine
- Plasma viscosity or ESR*
- Serum protein electrophoresis (to check for a paraprotein)
- sFLC assay (or urine BJP if sFLC is unavailable)**
- Serum immunoglobulins (IgG, IgA, and IgM)



* as recommended by the National Institute for Health and Care Excellence (NICE)³

** testing for serum or urinary light chains, as well as serum protein electrophoresis, is important because 20% of myeloma cases may be light chain only.

6. Interpreting test results

The critical hallmark of a monoclonal gammopathy is evidence of a monoclonal band on electrophoresis (paraprotein) or monoclonal excess of light chains in serum or urine. An abnormal serum protein electrophoresis and/or abnormal sFLC ratio will pick up ~98% of myeloma patients.⁹ Serum free light chain assay is not available to all GPs and so urinary BJP may be requested instead. Note: the latter is not as sensitive and some cases of light chain myeloma may not be detected.

If a monoclonal band is present, most laboratories will automatically perform immunofixation to define the Ig class (IgG, IgA and rarely IgM, D or E) and light chain type (kappa or lambda). Defining the Ig class early can help direct future investigations.

Serum immunoglobulins are typically reduced in myeloma (immunoparesis), except for the affected Ig type. Typical normal values for each of the tests covered above are summarised in Table 4.



Table 4. Typical normal ranges of myeloma screen blood tests

Blood test	Testing for	Normal range
Full blood count	Haemoglobin (men)	135–180 g/L
	Haemoglobin (women)	115–160 g/L
Serum Ig and protein electrophoresis	Paraprotein	0 g/L
Urea, electrolyte and creatinine	Urea	2.5–6.7 mmol/L
	Creatinine	70–150 µmol/L
	Calcium	2.12–2.6 µmol/L
sFLC assay	Kappa light chain (κ)	3.3–19.4 mg/L
	Lamda light chain (λ)	5.71–26.3 mg/L
	sFLC ratio (κ/λ)	0.26–1.65

7. Looking for trends and safety netting

In addition to new onset symptoms, underlying trends and combinations of blood test results may be helpful to consider. Such as:

- Falling haemoglobin levels and rising erythrocyte sedimentation rate (ESR) can occur in the two years prior to a myeloma diagnosis^{10, 11, 12}
- The combination of normal haemoglobin, plus normal ESR or plasma viscosity (PV) can help rule out myeloma.¹¹
- An increase in attendance by patients who rarely visit their GP, particularly for non-specific, vague and ongoing symptoms. For example, continuing and/or unexplained pain, presenting as generalised or localised, particularly in the back or ribs. Also recurring/persistent infections.
- Increasing pain in patients with chronic conditions such as arthritis, particularly if their usual analgesia has become less effective

The following general safety netting measures are important in myeloma, where symptoms can be non-specific in nature:

- Following up patients until their symptoms are explained, resolved or they are referred for further investigations
- Booking a follow-up appointment with the patient to discuss results of investigations
- Ensuring that patients know when to come back if symptoms do not resolve, and to reconsult if things change
- Checking patients' understanding of follow-up advice and that they are clear about what symptoms to look out for and report

8. When to refer

Referral needs to be in line with relevant national referral guidelines for cancer, which include both NICE guidance and Scottish government referral guidelines for suspected cancer.^{3,13}

Immediate or emergency referral is needed for any patient showing signs of acute kidney injury, significant hypercalcaemia or spinal cord compression as these clinical situations are emergencies.

Urgent referral to haematology on a suspected cancer referral pathway is needed for patients with one or more of the following:

- A new IgG paraprotein >15 g/L
- A new IgM or IgA paraprotein >10 g/L
- Identification of an IgD or IgE paraprotein (regardless of concentration)
- A significantly abnormal sFLC ratio (<0.1 or >7) or identification of BJP
- Any serum paraprotein <10 g/L but where there is clinical suspicion of myeloma
- Imaging confirming a lytic bone lesion or abnormality suspicious of myeloma
- Symptoms suggestive of underlying myeloma

Non-urgent/routine referral or discussion with clinical haematology may be appropriate for patients with a low level paraprotein or mildly abnormal sFLC ratio and no symptoms suggestive of myeloma. However, rechecking the serum or urine in 2–3 months is recommended to monitor the disease pattern and assess progression. Patients whose paraprotein concentration increases by >25% and >5 g/L or who develop symptoms will need an urgent referral to haematology as described above.

Response to results and referral pathway recommendations are summarised in Table 5. This table forms part of the Myeloma UK GP Myeloma Diagnostic Tool.¹⁴

Table 5. Response to results & referral guidance

<ul style="list-style-type: none"> Any paraprotein/abnormal sFLC ratio with significant symptoms indicative of an urgent problem (e.g. spinal cord compression, acute kidney injury) 	<p>Recommend immediate referral to Clinical Haematology</p>
<ul style="list-style-type: none"> Moderate concentration of paraprotein (IgG >15 g/L, IgA or IgM >10 g/L) Identification of an IgD or IgE paraprotein (regardless of concentration) Significant abnormal sFLC ratio (<0.1 or >7) <ul style="list-style-type: none"> Identification of BJP 	<p>Recommend urgent referral to Clinical Haematology (2-week rule)</p>
<ul style="list-style-type: none"> Minor concentration of paraprotein (IgG <15 g/L, IgA or IgM <10 g/L) without relevant symptoms Minor abnormal sFLC ratio (>0.1 and <7, but outside normal range) <p>This pattern is common in elderly patients</p>	<p>Recommend recheck serum and urine in 2–3 months to confirm pattern and assess any progression.</p> <p>Patients whose paraprotein concentration increases (25% and >5 g/L) or develop symptoms will need an urgent referral.</p> <p>Discuss with your Clinical Haematology Department if results not clear or concerns.</p>
<ul style="list-style-type: none"> No serum paraprotein Normal sFLC ratio (0.26–1.65)* <ul style="list-style-type: none"> No BJP Normal immunoglobulin levels <p>*some laboratories may have a slightly different reference range</p>	<p>Myeloma very unlikely but symptoms may still need to be investigated with other clinical specialties</p>

9. Managing MGUS in primary care

Patients with a diagnosis of MGUS require regular monitoring for signs of progression to myeloma or other associated disorders. The risk of progression from MGUS to myeloma is 1% per year and is dependent on a number of factors including:

- Type of paraprotein: IgA and IgM are associated with a higher risk of progression
- Higher levels of paraprotein
- Abnormal sFLC ratio

The most widely used risk stratification model for progression is summarised in Table 6 and can help guide the management and follow-up of MGUS patients.

Models of follow up

MGUS patients may be followed up by primary care, the hospital, or a combination of the two. Protocols and local commissioning can vary. For example, some low-risk MGUS patients are managed exclusively in primary care and referred only to secondary care if there are signs of progression. Others are managed solely in secondary care.

MGUS monitoring combines blood tests and checking for symptoms. Patients are referred to haematology if any of the following happen:

- Increased paraprotein concentration of >25% (a minimum absolute increase of 5 g/L)
- Symptoms indicative of myeloma occur (e.g. progressive back or generalised, unexplained pain)
- Unexplained anaemia, reduced renal function or hypercalcaemia occur

Table 6. Risk stratification model for progression from MGUS to myeloma¹⁵

Risk group (score)*	Risk of progression at 20 years (%)
Low (0)	5
Low-intermediate (1)	21
High-intermediate (2)	37
High (3)	58

* score 1 for each of the following:

- Serum paraprotein >15 g/L
- Non-IgG subtype
- Abnormal sFLC ratio (<0.26 or >1.65)

Current guidance suggests a repeat check at 6 months and then annual follow-ups thereafter, although the interval can be longer for patients with low-risk MGUS.¹⁶

Information and reassurance are vitally important in helping manage the feelings of anxiety and uncertainty that patients experience when diagnosed with a pre-malignant condition such as MGUS. It is important that patients understand the symptoms to look out for and report, should they occur. Myeloma UK provides an information sheet on MGUS, which includes symptom awareness and living with an MGUS diagnosis.

10. Other conditions associated with monoclonal proteins

Monoclonal gammopathy can be associated with other systemic disorders in the absence of progression to myeloma. These conditions are broadly termed monoclonal gammopathy of clinical significance (MGCS). Although the gammopathy is benign, there may be symptoms and complications that require early intervention. These conditions include:

- Amyloid light-chain (AL) amyloidosis (see below)
- A variety of renal syndromes termed monoclonal gammopathy of renal significance (MGRS)
- POEMS syndrome (**P**eripheral neuropathy, **O**rganomegaly, **E**ndocrinopathy, **M** protein, **S**kin changes).

The typical organs affected are heart, kidneys, nerves, and skin.

A patient with MGUS developing unexplained heart failure, renal impairment (especially with proteinuria or haematuria), progressive peripheral neuropathy or autonomic neuropathy requires referral for further investigation for MGCS.

Unexplained inflammatory and skin disorders may also be MGCS syndromes.

Patients who develop symptoms of MGCS (or patients with MGUS who have been identified as high-risk by the haematology team) should have a urine protein:creatinine or albumin:creatinine ratio, and a serum NTproBNP test performed.

AL amyloidosis

AL amyloidosis is a condition caused when abnormal plasma cells in the bone marrow produce amyloid protein, and the protein is deposited as fibrils in organs around the body. This causes damage to organs and reduces function. The most common organs and tissues affected are the heart, kidneys, liver, GI tract, and nerves.

Around 500–600 people are diagnosed with AL amyloidosis each year in the UK. Because it arises from plasma cells, its diagnosis and management differs from other, less common, forms of amyloidosis such as wild-type transthyretin amyloidosis (ATTRwt), hereditary amyloidosis (ATTR) and AA amyloidosis. It is highly likely that AL amyloidosis is underdiagnosed.

Around 10–20% of patients with myeloma develop co-existing AL amyloidosis. There is also the chance that patients with MGUS can develop AL amyloidosis. Thus, routine monitoring of MGUS patients should include looking out for signs of AL amyloidosis, as well as myeloma.

Spotting AL amyloidosis

As with myeloma and MGUS, AL amyloidosis is more common in older adults. Patients usually present with organ dysfunction, most typically renal impairment, cardiomyopathy, cholestatic hepatopathy, and peripheral or autonomic neuropathy. Signs and symptoms vary widely and can include:

- Feeling generally unwell: fatigue, weakness, weight loss
- Oedema in legs/abdomen
- Shortness of breath
- Dizziness, hypotension
- Peripheral neuropathy
- Nausea, diarrhoea, or constipation
- Bruising of the skin around the eyes
- Enlarged tongue

Its varying presentation, rarity and often insidious onset, make AL amyloidosis a hard condition for doctors to spot and diagnose. As with myeloma, early diagnosis is key to effective intervention.

Laboratory tests and imaging are similar to those required to diagnose myeloma (see page 12). If you suspect a patient has amyloidosis, look for proteinuria on urine dipstick and heart failure with NTproBNP. These tests will pick up the majority of patients with AL amyloidosis. Serum protein electrophoresis, immunofixation and sFLC should all be measured if AL amyloidosis is suspected. An abnormal kappa:lambda ratio on sFLC assay is an indication of a light chain abnormality. Other test results which may indicate organ dysfunction include abnormal renal function or liver function or albuminuria.

A tissue biopsy is always necessary to establish the diagnosis of AL amyloidosis, along with other tests to assess the degree of amyloid involvement, such as the SAP (Serum amyloid P component) scan, which is carried out at the specialist National Amyloidosis Centre (NAC) at the Royal Free Hospital in London. If amyloidosis is suspected, an urgent referral to haematology, renal or cardiology (organ-dependent) should be made, or contact made with a specialist amyloidosis centre, such as the NAC.

Treatment and prognosis

Treatment for AL amyloidosis is managed by the local haematology team or regional amyloidosis service, in collaboration with other specialists such as cardiologists and renal physicians. The approach is similar to myeloma, with the aim of reducing light chain production and improving organ function. Patients usually start with a combination of bortezomib, chemotherapy and steroids. Patients are treated locally but are also reviewed and monitored periodically at a tertiary centre such as the NAC.

As with myeloma, AL amyloidosis is treatable but not currently curable. The prognosis can vary widely and is closely connected to the degree of organ involvement, particularly the heart, and how early the amyloidosis is diagnosed. Prognosis is poor if diagnosis is not made early. Survival can be less than two years for patients with significant cardiac amyloidosis, hence the need for urgent referral and treatment.

Further information

If you would like to learn more about AL amyloidosis, we also have an RCPATH-accredited e-learning module, available at:

 <https://learninghub.nhs.uk/Resource/35342/Item>

11. Managing patients with myeloma in primary care

Patients with active and smouldering myeloma are managed by a haematologist but will still be seen in primary care for management of other conditions, depending on their needs.

Myeloma treatment consists of a combination of drugs; typically, this will be chemotherapy, steroids and treatments such as proteasome inhibitors and/or immunomodulatory drugs. Younger, fitter patients are usually offered an autologous stem cell transplant after initial chemotherapy. Myeloma treatment has a variety of side effects, which are monitored by the haematology team, and may be evident if the patient is seen in primary care.

As a relapsing remitting disease, myeloma patients will typically have periods of time on treatment, but also periods in remission or with stable disease. The onset of new symptoms and potential myeloma progression should always be a consideration during GP appointments.

Points to be aware of when seeing myeloma patients include:

- ❑ Increased risk of venous thromboembolic events, particularly when patients are receiving myeloma treatment with chemotherapy and steroids
- ❑ Side effects of high-dose steroids, including the risk of diabetes, or changes in a patient's existing diabetes management while on steroids
- ❑ Risk of neutropenic sepsis if on chemotherapy or following stem cell transplant
- ❑ Ongoing susceptibility to infections and a reduced threshold for using antibiotics
- ❑ Vaccinations – myeloma patients are recommended to have the seasonal influenza vaccine annually, and the pneumococcal vaccine every five years. Shingrix® (Shingles vaccine) should be offered to individuals 50 years and above, according to local policy. COVID-19 vaccination is required in line with the relevant government guidance.
- ❑ Vaccinations following stem cell transplantation – repeat childhood vaccinations may be advised, together with Shingrix® vaccine, according to local policy.
- ❑ Chronic myeloma symptom management, including pain, neuropathy and fatigue
- ❑ Avoidance of non-steroidal anti-inflammatory drugs (NSAIDs), which can worsen renal function
- ❑ Psychosocial effects of diagnosis and treatment, and the need for patient and carer support

12. References

1. Rajkumar et al. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*, 15: e538–48
2. Kyle et al. (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *N Engl J Med*, 356(25): 2582–90
3. National Institute for Health and Care Excellence (2015) Suspected cancer: recognition and referral. NICE guidelines [NG12]. <https://www.nice.org.uk/guidance/ng12>
4. Neal et al. (2014) Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. *Br J Cancer*, 110(3): 584–592.
5. National Cancer Intelligence Network. Routes to Diagnosis 2006–2016 workbook (a). http://www.ncin.org.uk/publications/routes_to_diagnosis
6. Howell et al. (2017) Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. *Br J Haematol*, 177(1): 67–71
7. Abel et al. (2017) Emergency diagnosis of cancer and previous general practice consultations: insights from linked patient survey data. *Br J of Gen Pract*, 67(659): 377–387
8. Shephard et al. (2015) Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case-control study using electronic records. *Br J Gen Pract*, 65(631): e106–e113
9. Heaney et al. (2020) Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels. *Haematologica*, 105(4): e169–e171

10. Atkin et al. (2020) Change in blood test results prior to diagnosis in multiple myeloma. *Clinical Medicine*, 20 (Suppl 2) s99–s100
11. Koshiaris et al. (2018) Early detection of multiple myeloma in primary care using blood tests: a case-control study in primary care. *Br J Gen Pract*, 68 (674): e586–e593
12. Edgren et al. (2010) Pattern of declining hemoglobin concentration before cancer diagnosis. *Int J Cancer*, 127(6): 1429–36
13. Scottish Government: Scottish referral guidelines for suspected cancer. <https://www.gov.scot/publications/scottish-referral-guidelines-suspected-cancer-january-2019>
14. Myeloma UK GP Myeloma Diagnostic Tool. <https://academy.myeloma.org.uk/resources/gp-myeloma-diagnostic-tool>
15. Rajkumar (2005) MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. *Hematology Am Soc Hematol Educ Program*, 340–5
16. Stern et al. (2023) The Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum. Investigation and management of the monoclonal gammopathy of undetermined significance. *Br J Haematol*, 2023; 00: 1–11. <https://doi.org/10.1111/bjh.18866>

13. Further information

Educational Resources

- ★ Myeloma UK resources for GPs and other healthcare professionals are available at academy.myeloma.org.uk
These include:
 - GP Diagnostic Tool
 - Myeloma Diagnosis Pathway
 - Macmillan Ten Top Tips

- ★ Educational modules for professionals:
 - Gateway C Myeloma course (for primary care)
<https://www.gatewayc.org.uk/courses/myeloma>
 - BMJ Myeloma Module (for primary care)
<https://new-learning.bmj.com/course/10066091>
 - AL amyloidosis: what you need to know
<https://learninghub.nhs.uk/Resource/35342/Item>

- ★ Medical animations
<https://academy.myeloma.org.uk/library/medical-animations>

- ★ Cancer Research UK myeloma statistics
<https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma>

- ★ Haematological Malignancy Research Network (HMRN) myeloma factsheets
<https://hmrn.org/factsheets#myeloma>

Guidelines

- ▣ NICE guideline [NG12] suspected cancer: recognition and referral
<https://www.nice.org.uk/guidance/ng12>
- ▣ NICE guideline [NG35] Myeloma: diagnosis and management
<https://www.nice.org.uk/guidance/ng35>
- ▣ Scottish Government: Scottish referral guidelines for suspected cancer
<https://www.gov.scot/publications/scottish-referral-guidelines-suspected-cancer-january-2019>
- ▣ British Society for Haematology (BSH) and UK Myeloma Forum (UKMF) guidelines on the diagnosis, investigation and initial treatment of myeloma
<https://b-s-h.org.uk/guidelines/guidelines/guidelines-on-the-diagnosis-investigation-and-initial-treatment-of-myeloma>
- ▣ BSH guidelines for the use of imaging in the management of patients with myeloma
<https://b-s-h.org.uk/guidelines/guidelines/use-of-imaging-in-the-management-of-patients-with-myeloma>
- ▣ BSH and UKMF guidelines for screening and management of late and long-term consequences of myeloma and its treatment
<https://b-s-h.org.uk/guidelines/guidelines/guidelines-for-screening-and-management-of-late-and-long-term-consequences-of-myeloma-and-its-treatment>
- ▣ BSH Good Practice Paper: Investigation and management of the monoclonal gammopathy of undetermined significance
<https://b-s-h.org.uk/guidelines/guidelines/investigation-and-management-of-monoclonal-gammopathy-of-undermined-significance>

Patient information

- i** Tests and investigations in myeloma Infoguide
<https://myeloma.org.uk/documents/tests-and-investigations-in-myeloma-infoguide>

- i** MGUS Infosheet
<https://myeloma.org.uk/documents/monoclonal-gammopathy-of-undetermined-significance-mgus-infosheet>

- i** MGUS Diary
<https://myeloma.org.uk/mgusdiary>

- i** Infopack for newly diagnosed myeloma patients
<https://myeloma.org.uk/documents/infopack-for-newly-diagnosed-patients>

- i** Smouldering myeloma Infosheet
<https://myeloma.org.uk/documents/smouldering-myeloma-infosheet>

- i** MGCS Infosheet
<https://myeloma.org.uk/documents/monoclonal-gammopathy-of-clinical-significance-mgcs-infosheet>

- i** AL amyloidosis: Your Essential Guide
<https://myeloma.org.uk/documents/al-amyloidosis-your-essential-guide>

The full list of our publications for patients can be found at myeloma.org.uk/publications

Notes



Myeloma, MGUS & related conditions: A Guide for GPs



Myeloma UK is the only organisation in the UK dealing exclusively with the incurable blood cancer myeloma and related conditions.

We deliver better patient outcomes through our dedicated programmes covering early diagnosis, research, treatment access, healthcare services improvement, and patient information and support.

For any queries or additional resources for healthcare professionals on myeloma and unrelated conditions:

 academy.myeloma.org.uk

 academy@myeloma.org.uk

Myeloma UK
22 Logie Mill,
Beaverbank Business Park,
Edinburgh EH7 4HG

 0131 557 3332

 myelomauk@myeloma.org.uk

 myeloma.org.uk

Registered Charity No: SC026116

Written by Myeloma UK in collaboration
with members of the Myeloma UK Early
Diagnosis Steering Committee.

Published by:	Myeloma UK
Publication date:	September 2021
Last updated:	July 2023
Review date:	July 2025